Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.
NEW YORK (TheStreet) — Here’s what Jim Cramer had to say about some of the stocks callers offered up during the “Mad Money Lightning Round” Thursday evening:
Royal Caribbean Cruises (RCL): “They’re taking a lot of share and I like them.”
Take-Two Interactive (TTWO): “They’re doing a great job and I think they can go much higher.” KeyCorp (KEY): “It’s up real big and it doesn’t do well with this yield curve.” Celldex Therapeutics (CLDX): “I say to hold onto this stock. I’m not a seller.” ExOne (XONE): “That’s a 3D play. I like this one for speculation only.” To read a full recap of “Mad Money” on CNBC, click here. To sign up for Jim Cramer’s free Booyah! newsletter with all of his latest articles and videos please click here. To watch replays of Cramer’s video segments, visit the Mad Money page on CNBC. — Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
5 Best Managed Healthcare Stocks To Watch For 2016: Allscripts Healthcare Solutions Inc.(MDRX)
Allscripts Healthcare Solutions, Inc. provides clinical, financial, connectivity, and information solutions and related professional services to hospitals, physicians, and post-acute organizations primarily in the United States and Canada. The company?s integrated clinical software applications include acute care electronic health records, clinical and practice management solutions, revenue cycle management software, clearinghouse services, stand-alone electronic prescribing, and document imaging solutions, as well as various solutions for home care, hospice, skilled nursing, and other post-acute organizations. It also provides electronic medical records software; practice management software; electronic claims administration services; related installation and training services; hosting services for its software and outsourced solutions; and information technology outsourcing services. In addition, the company also resells related hardware products. Allscripts Healthcare S olutions, Inc. is headquartered in Chicago, Illinois.
- [By George Putnam]
After a large acquisition, made in 2010, didn’t work out as planned, Allscripts Healthcare Solutions (MDRX) put itself up for sale in early 2012. This created concern among its clients, and potential clients, and eventually led to the replacement of its long-time CEO in December 2012.
- [By Ben Levisohn]
Which might help explain why Quality Systems has dropped 0.1% to $17.98 today, even as Allscripts Healthcare Solutions (MDRX) has gained 1.7% to $16.15 and Cerner (CERN) has risen 3.4% to $55.42.
- [By Selena Maranjian]
Other companies didn’t do as well last year, but could see their fortunes change in the coming years. Allscripts Healthcare Solutions (NASDAQ: MDRX ) , which delivers electronic health records (EHR) products and services, slid 20%. The company has been lagging its peers, it was a poor performer in 2012, and its latest earnings report wasn’t too impressive. On the plus side, some of its insiders have been buying shares.
- [By Keith Speights]
Cerner’s recent stock performance trounces that of other publicly traded companies, including Allscripts (NASDAQ: MDRX ) , Greenway Medical (NYSE: GWAY ) , and Quality Systems (NASDAQ: QSII ) . Only athenahealth (NASDAQ: ATHN ) gives Cerner a run for its money over the past year.
5 Best Managed Healthcare Stocks To Watch For 2016: Rockwell Medical Technologies Inc.(RMTI)
Rockwell Medical Technologies, Inc. manufactures, sells, and distributes hemodialysis concentrate solutions and dialysis kits primarily in the United States, Latin America, Asia, and Europe. The company?s hemodialysis product duplicates kidney function in patients with failing kidneys, known as end stage renal disease, an advanced stage of chronic kidney disease; and dialysis solutions are used to maintain life, remove toxins, and replace nutrients in the dialysis patient?s bloodstream. Its products include Renal Pure and CitraPure liquid acid concentrate, Dri-Sate dry acid concentrate and mixing systems, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrates; and various ancillary products comprising blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies. The company also has a license to manufacture and sell soluble ferric pyrophosphate (SFP), a Phase III clinical trial p r oduct to improve the treatment of dialysis patients with iron deficiency. Rockwell Medical Technologies sells its products to domestic hemodialysis providers through direct sales people and independent sales representation companies, as well as through independent sales agents and distributors internationally. The company was founded in 1995 and is based in Wixom, Michigan.
- [By John Udovich]
Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA) and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM).
- [By Jake L’Ecuyer]
Rockwell Medical (NASDAQ: RMTI) was also down, falling 19.90 percent to $10.80 after Brean Capital initiated the company at a Sell rating and a $4 price target.
5 Best Managed Healthcare Stocks To Watch For 2016: Summer Infant Inc.(SUMR)
Summer Infant, Inc., through its subsidiaries, engages in the design, marketing, and distribution of branded juvenile health, safety, and wellness products primarily in North America and the United Kingdom. It offers products in various product categories, including nursery audio/video monitors, safety gates, durable bath products, bed rails, nursery products, booster and potty seats, bouncers, travel accessories, high chairs, swings, feeding products, car seats, and nursery furniture, as well as infant thermometers, related health and safety products, cribs, baby gear, swaddling blankets, and bottles. The company sells its products principally under the Summer Infant, Carter?s, and Disney brand names through mass merchant retailers and specialty retailers, as well as directly to consumers. Summer Infant, Inc. is headquartered in Woonsocket, Rhode Island.
- [By Lisa Levin]
Summer Infant (NASDAQ: SUMR) shares dropped 3.69% to $3.65 after the company reported Q2 results.
Nordstrom (NYSE: JWN) tumbled 3.86% to $66.04 after the company reported Q2 results. The company reported earnings of $183 million, or $0.95 per share.
5 Best Managed Healthcare Stocks To Watch For 2016: Dassault Systemes SA (DSY)
Dassault Systemes SA provides software solutions and consulting services. The Company’s global customer base includes companies primarily in 11 industrial sectors: Aerospace & Defense, Transportation & Mobility, Marine & Offshore, Industrial Equipment, High Tech, Architecture, Engineering & Construction, Consumer Goods Retail, Consumer Packaged goods Retail, Life Sciences, Energy, Process & Utilities, Financial & Business services. To serve these industries, the Company has developed a broad software applications portfolio, organized in brands, in order to provide comprehensive solutions responding to the extensive requirements of product development: Design, Realistic Simulation, Virtual Manufacturing and Production, Collaborative Innovation, Lifelike Experiences and Information Intelligence. In July 2013, it acquired Apriso. In September 2013, it acquired Safe Technology Ltd. In January 2014, the Company acquired 84% interest in Realtime Technology AG. Advisors’ Opinion:
- [By Julia Leite]
The FTSE/JSE Africa All Shares Index fell 1.8 percent, the most since July 5. Discovery Ltd. (DSY), South Africa’s largest medical-insurance provider, sank 9.1 percent after saying profit will be as much as 10 percent lower than the previous period.
5 Best Managed Healthcare Stocks To Watch For 2016: Prometheus RxDx Corp (RXDX)
Prometheus RxDx Corp., incorporated in June 2009, is a wholly owned subsidiary of Prometheus Laboratories Inc. The Company is engaged in the development and commercialization of pharmaceutical and diagnostic products that enable physicians to provide individualized patient care. It focuses on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology. It operates in two segments: the pharmaceutical products segment that markets and sells prescription drugs, and the diagnostic testing services segment, which includes specific immunoassays to detect and differentiate diseases, pharmacogenetic testing and drug metabolite monitoring. The pharmaceutical products for gastrointestinal diseases and disorders includes ENTOCORT EC (budesonide) Capsules, which is indicated for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon, and LOTRONEX (alosetron hydrochloride) Tablets, for use in female patients with severe diarrhea-predominant irritable bowel syndrome (IBS).
Gastroenterology Pharmaceutical Products
The pharmaceutical products for gastrointestinal diseases and disorders include Entocort EC for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or ascending colon and Lotronex for treatment of a subset of women with severe diarrhea-predominant IBS. The Company sells but does not market, several other pharmaceuticals, including Imuran, Helidac Therapy, and Ridaura, in addition to a number of other diagnostic tests. It also manufactures a generic mercaptopurine product, which is sold through a third-party distributor. It only offers pharmaceutical products in the United States. It began selling Proleukin in February 2010 under an exclusive distribution and promotion agreement with Novartis. Proleukin is a recombinant human interleukin-2 for treatment in adults with metastatic renal cell carcinom a and metastatic melanoma. Proleukin therapy is a form of im! munotherapy that uses the body’s natural immune system to fight cancer. In December 2010, it signed an agreement with ThePharmaNetwork, LLC, to sell Trandate and Zyloprim.
Entocort EC is the Food and Drug Association- approved drug indicated for the induction and maintenance of clinical remission in mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon. Entocort EC consists of an encapsulated formulation of budesonide granules, a glucocorticosteroid. Entocort EC is designed to release primarily in the ileum and/or the ascending colon, so that as little as 10% of the drug enters systemic circulation. Entocort EC may benefit patients by reducing glucocorticosteroid-related side effects. Lotronex is indicated for use only in women with severe diarrhea-predominant IBS who have not responded adequately to conventional therapy, whose IBS symptoms are chronic, and who have had other gastrointestinal medical conditions ruled out.
Imuran is indicated for adjunctive use in the prevention of rejection in kidney transplants and in the management of active rheumatoid arthritis. Although Imuran is not indicated for the treatment of IBD and the Company does not promote it for that indication, physicians often prescribe it for various forms of IBD, including Crohn’s disease and ulcerative colitis, as well as other autoimmune disorders. Imuran is prescribed primarily by gastroenterologists, transplant surgeons, nephrologists, rheumatologists and internal medicine specialists. Helidac Therapy (Hediac), when taken with a hydrogen (H2 ) antagonist, is indicated for the eradication of Helicobacter pylori, or H. pylori, bacteria, which causes peptic ulcers, and for patients with duodenal ulcer disease. Ridaura is approved for the treatment of active classical or definite rheumatoid arthritis in adults. Ridaura is the oral formulation of a gold salt available for the treatment of rheumatoid arthritis for patients who have not responded adequately to one or mor! e non-ste! roidal anti-inflammatory drugs. Mercaptopurine is approved for maintenance for acute lymphatic leukemia as part of a combination regimen and, although it is not indicated for the treatment of certain gastrointestinal diseases and it does not promote it for those indications, physicians often prescribe it for various forms of IBD, including Crohn’s disease and ulcerative colitis.
Trandate is approved for the management of high blood pressure, or hypertension. Trandate can be used alone or in combination with other anti-hypertensive agents, particularly thiazide and loop diuretics. Trandate is typically prescribed by cardiologists, family practitioners and internists. Trandate competes both with generics and many other drugs used to treat hypertension. In December 2010, the Company signed an agreement with ThePharmaNetwork, LLC, to sell Trandate. Zyloprim reduces serum and uric acid levels and is approved for the management of patients with gout, patients receiv ing certain types of chemotherapy to leukemia, lymphoma and other cancers, and patients with kidney or urinary stones. Zyloprim is prescribed by orthopedic specialists, rheumatologists, podiatrists, nephrologists and family practitioners.
Gastroenterology Diagnostic Testing Services
The diagnostic testing services are designed to aid physicians in making diagnoses with non-invasive testing and to assist them in determining therapy treatment and management, thereby helping a physician customize treatment to an individual patient. The Company performs all its diagnostic testing services in its laboratory located in San Diego, California. During the year ended December 31, 2010, it launched PROMETHEUS Crohn’s Prognostic, the serogenetic prognostic test for Crohn’s disease. The Company offers three celiac tests to physicians, including antibody tests, a genetics test and a panel that combines both the antibody and genetics tests.
The Company competes with Quest Diagnostics Incorporated and La! boratory ! Corporation of America Holdings
- [By James E. Brumley]
Quick – what do CytRx Corporation (NASDAQ:CYTR) and Ignyta Inc. (NASDAQ:RXDX) have in common? Yes, they’re both biotech stocks, but that’s not the absolute best answer right now. The most meaningful common element between RXDX and CYTR right now is, each is on the verge of a big technical breakout and deserves a spot on your watchlist. Here’s a closer look at each.